Publications in collaboration with researchers from Centro Nacional de Investigaciones Oncológicas (78)

2026

  1. Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC

    Journal of Thoracic Oncology, Vol. 21, Núm. 7

  2. Emerging Targeted Therapies for HER2-Mutant NSCLC

    Journal of Thoracic Oncology

2025

  1. Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC

    JTO Clinical and Research Reports, Vol. 6, Núm. 3

  2. Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors

    Investigational New Drugs, Vol. 43, Núm. 4, pp. 955-967

  3. The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

    EMBO Molecular Medicine, Vol. 17, Núm. 12, pp. 3377-3406

2024

  1. CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

    OncoImmunology, Vol. 13, Núm. 1

  2. Correction to: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Drugs, (2024), 84, 5, (527-548), 10.1007/s40265-024-02030-7)

    Drugs

  3. Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2872-2883

  4. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

  5. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

    Drugs, Vol. 84, Núm. 5, pp. 527-548

  6. Telomere-based risk models for the early diagnosis of lung cancer

    Heliyon, Vol. 10, Núm. 24

2023

  1. Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

    Cancers, Vol. 15, Núm. 5

  2. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 3, pp. 143-159

  3. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86

  4. Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

    Cancers, Vol. 15, Núm. 23

  5. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  6. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  7. Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models

    International Journal of Molecular Sciences, Vol. 24, Núm. 16

  8. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2022

  1. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 163-192